Pharsight Strengthens European Consulting Team

Henri Merdjan Appointed to Head Regulatory Analysis and Reporting in Europe

ST. LOUIS--(BUSINESS WIRE)-- Pharsight, a market-leading provider of software and scientific consulting services to improve productivity and decision-making in clinical drug development, announced today that it has expanded its presence in the European market by appointing Henri Merdjan as Senior Director of Consulting Services, Europe. In this role, Mr. Merdjan will lead the Company’s European business development for regulatory-compliant PK/PD analysis and reporting services.

Mr. Merdjan brings to Pharsight more than 25 years of drug development experience with a variety of major companies including Novexel, Servier, and Sandoz. Prior to joining Pharsight, Mr. Merdjan was Vice President, Drug Metabolism and Pharmacokinetics at Novexel, a biotechnology company focused on anti-infectives. At Servier he created a Modeling and Simulation department and was responsible for an R&D facility focused on bioanalysis, preclinical and clinical DMPK, and regulatory toxicokinetics.

"Pharsight’s capabilities in modeling and simulation are becoming mainstream practices in a growing number of drug development organizations," said Mr. Merdjan. “I look forward to working with our European client base of pharmaceutical and biotechnology companies to more efficiently develop their product pipelines.”

“Henri’s extensive pharmaceutical industry background in clinical pharmacology and modeling and simulation will allow us to further grow Pharsight’s European consulting business,” said Rene Bruno, Ph.D., Managing Director of Pharsight Consulting Services in Europe. “We believe Henri’s leadership will be particularly valuable as we execute on our plans to expand the services we provide to customers to accelerate drug development and improve productivity and decision-making. We are very excited to welcome Henri to Pharsight.”

About Pharsight Consulting

Pharsight Consulting Services is the world’s largest and most experienced pharmacometric consulting group, a global team of experts dedicated to supporting strategic development decisions and submission-ready analyses for new drug approval. Pharsight’s 40 consultants apply quantitative modeling and simulation to guide client’s critical drug positioning, program strategy and clinical trial design decisions from pre-clinical to post-launch. The group’s collective experience spans all major therapeutic areas, more than 80 disease indications, and 130 drug classes. Pharsight consulting staff leverages expertise in Pharsight’s leading software tools and in the disciplines of pharmacology, drug and disease modeling, biostatistics, strategic decision-making and regulatory strategy.

About Pharsight

Pharsight, a Certara™ company, is a market-leading provider of software products and scientific consulting services to help pharmaceutical and biotechnology companies improve their drug development process, regulatory compliance and strategic decision-making. Established in 1995, the company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products. Headquartered in St. Louis, Missouri, with more than 1200 customers worldwide, Pharsight products and services are used by all of the world’s top 50 pharmaceutical firms. More information about Pharsight is available at www.pharsight.com.

About Certara

Certara is dedicated to improving human health through a broad spectrum of products and services, from molecular discovery to clinical research. Formed in 2008, Certara unites Tripos and Pharsight Corporation. More information about Certara is available at www.certara.com.

Registered Trademarks and Trademarks

Pharsight and Certara are trademarks or registered trademarks of Tripos, L.P. All other brands and product names are trademarks or registered trademarks of their respective holders.



CONTACT:

Pharsight
Adam Rutkin, 650-314-3752
Director of Marketing
[email protected]

KEYWORDS:   United States  Europe  North America  Missouri

INDUSTRY KEYWORDS:   Technology  Software  Health  Biotechnology  Pharmaceutical  Professional Services  Consulting

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.